Brief: Regulus Therapeutics Announces First Patient Dosed In Third Cohort
02/11/2023 12:54
Nov 2 (Reuters) - Regulus Therapeutics Inc RGLS.O :
* REGULUS THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
THIRD
COHORT OF PHASE 1B MULTIPLE-ASCENDING DOSE (MAD) CLINICAL TRIAL
OF RGLS8429 FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC
KIDNEY DISEASE (ADPKD)
* REGULUS THERAPEUTICS INC - PHASE 1B MAD CLINICAL TRIAL
REMAINS
ON TRACK
* REGULUS THERAPEUTICS INC - LOOK FORWARD TO SHARING TOPLINE
DATA
FROM SECOND COHORT OF STUDY IN Q1 OF 2024
Source text for Eikon: ID:nPn59nkFsa
Further company coverage: RGLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regulus Therapeutics
See all newsBrief: Novartis Completes Acquisition Of Regulus Therapeutics
Brief: Novartis Announces Expiration Of Hart-Scott-Rodino Waiting Period Of Regulus Therapeutics Tender Offer
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics
Regulus Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Regulus Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview